logo
Plus   Neg
Share
Email

Roche 9-month Sales Up 10%; Raises FY19 Outlook - Quick Facts

Roche Holding AG (RHHBY) reported that Group sales increased 10 percent at constant exchange rates and 9 percent in Swiss francs, in the first nine months of 2019, due to new products. Pharmaceuticals Division sales were up 12 percent, driven by high demand for recently launched medicines, mainly Ocrevus, Hemlibra, Tecentriq and Perjeta. Diagnostics Division sales grow 4 percent, primarily due to its immunodiagnostic testing portfolio.

In the first nine months of 2019, Group sales rose 10 percent to 46.1 billion Swiss francs. Sales in the Pharmaceuticals Division increased 12 percent to 36.6 billion francs. Diagnostics Division sales increased 4 percent to 9.5 billion francs.

Based on the strong demand for new medicines and continued progress of product pipeline, Roche now expects sales to grow in the high-single digit range, at constant exchange rates, for 2019.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Polaris Industries Inc. is recalling certain Ranger and General Utility, as well as All-Terrain vehicles citing risks of crash, the U.S. Consumer Product Safety Commission said in a statement. The Medina, Minnesota-based company has called back about 26,730 units of Model Year 2019 - 2020 Ranger XP 1000 & Model Year 2020 General XP 1000 Utility vehicles. Gilead Sciences Inc. (GILD) said Friday that the European Commission has granted conditional marketing authorization for Veklury or remdesivir as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19. FedEx is asking NFL team Washington Redskins to change its name for its racist connotations. The delivery services company, which is a major sponsor for the team, made the suggestion following increasing pressure from its investors amid the ongoing protests against racial injustice and inequality that arose from the killing of African-American George Floyd.
Follow RTT